Evidence map›Paper›PMID 36142851›Full record

ArticleInternational journal of molecular sciences2022

Fullerenol C

Jacek Grebowski, Paulina Kazmierska-Grebowska, Natalia Cichon, Anna Konarska, Marian Wolszczak, Grzegorz Litwinienko

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. The fullerenol CJournal of bioenergetics and biomembranes · 2026
    Article
  3. Article
  4. Metallofullerenol ScAdvanced healthcare materials · 2026
    Article
  5. Effect of Fullerenol CMolecules (Basel, Switzerland) · 2025
    Article
  6. Evaluation of Immunotoxicity of Fullerenol CBulletin of experimental biology and medicine · 2025
    Article
  7. Article
  8. Article
  9. Molecular and Macromolecular Interactions of Carbon-Based Nanostructures.International journal of molecular sciences · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Jacek GrebowskiDepartment of Molecular Biophysics, Faculty of Biology and Environmental Protection, University of Lodz, Pomorska 141/143, 90-236 Lodz, Poland.ORCID 0000-0001-5407-9533
Paulina Kazmierska-GrebowskaDepartment of Neurobiology, Faculty of Biology and Environmental Protection, University of Lodz, Pomorska 141/143, 90-236 Lodz, Poland.
Natalia CichonBiohazard Prevention Centre, Faculty of Biology and Environmental Protection, University of Lodz, Pomorska 141/143, 90-236 Lodz, Poland.ORCID 0000-0002-0139-2451
Anna KonarskaInstitute of Applied Radiation Chemistry, Technical University of Lodz, Wroblewskiego 15, 93-590 Lodz, Poland.
Marian WolszczakInstitute of Applied Radiation Chemistry, Technical University of Lodz, Wroblewskiego 15, 93-590 Lodz, Poland.
Grzegorz LitwinienkoFaculty of Chemistry, University of Warsaw, Pasteura 1, 02-093 Warsaw, Poland.ORCID 0000-0002-5523-0888
University of Łódź · PLLodz University of Technology · PLUniversity of Warsaw · PL

Funding

National Science Centre NCN grant No. 2019/35/D/ST4/02627
6 · The paper itself

Abstract

Ionizing radiation (IR) can pass through the human body easily, potentially causing severe damage to all biocomponents, which is associated with increasing oxidative stress. IR is employed in radiotherapy; however, in order to increase safety, it is necessary to minimize side effects through the use of radioprotectors. Water-soluble derivatives of fullerene exhibit antiradical and antioxidant properties, and these compounds are regarded as potential candidates for radioprotectors. We examined the ability of fullerenol C60(OH)36 to protect human erythrocytes, including the protection of the erythrocytal antioxidant system against high-energy electrons. Human erythrocytes irradiated with high-energy [6 MeV] electrons were treated with C60(OH)36 (150 µg/mL), incubated and haemolyzed. The radioprotective properties of fullerenol were determined by examining the antioxidant enzymes activity in the hemolysate, the concentration of -SH groups, as well as by determining erythrocyte microviscosity. The irradiation of erythrocytes (650 and 1300 Gy) reduces the number of thiol groups; however, an attenuation of this harmful effect is observed (p < 0.05) in the presence of C60(OH)36. Although no significant effect of fullerenol was recorded on catalase activity, which was preserved in both control and test samples, a more active protection of other enzymes was evident. An irradiation-induced decrease in the activity of glutathione peroxidase and glutathione reductase became an increase in the activity of those two enzymes in samples irradiated in the presence of C60(OH)36 (p < 0.05 and p < 0.05, respectively). The fourth studied enzyme, glutathione transferase, decreased (p < 0.05) its activity in the irradiated hemolysate treated with C60(OH)36, thus, indicating a lower level of ROS in the system. However, the interaction of fullerenol with the active centre of the enzyme cannot be excluded. We also noticed that radiation caused a dose-dependent decrease in the erythrocyte microviscosity, and the presence of C60(OH)36 reduced this effect (p < 0.05). Overall, we point to the radioprotective effect of C60(OH)36 manifested as the protection of the antioxidant enzymes of human erythrocytes against IR-induced damage, which has not been the subject of intense research so far.

Indexed as

FullerenesAntioxidantsCatalaseElectronsErythrocytesGlutathione PeroxidaseGlutathione ReductaseGlutathione TransferaseHumansOxidative StressReactive Oxygen SpeciesSulfhydryl CompoundsWaterAntioxidantsCatalaseFullerenesfullerenolGlutathione PeroxidaseGlutathione ReductaseGlutathione TransferaseReactive Oxygen SpeciesSulfhydryl CompoundsWaterantioxidant enzymeserythrocytesfullerenolionizing radiationradioprotection

Identifiers

PMID36142851
PMCPMC9502585
OpenAlexW4296463536

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.